Financials data is unavailable for this security.
Inc stmt in USDIncome statement in USD
Year on year
Amgen Inc grew revenues 6.14% from 21.66bn to 22.99bn. In addition the company has reduced the cost of goods sold as a percent of sales, selling, general and administrative expenses as a percent of sales and interest paid as a percent of sales. These improvements contributed to 11.28% net income growth from 6.94bn to 7.72bn.
|Net profit margin||34.43%|
|Return on assets||10.32%|
|Return on equity||26.61%|
|Return on investment||11.79%|
Cash flow in USD
In 2016, cash reserves at
Amgen Inc fell by 903.00m. However, the company earned 10.35bn from its operations for a Cash Flow Margin of 45.04%. In addition the company used 8.66bn on investing activities and also paid 2.60bn in financing cash flows.
|Cash flow per share||13.37|
|Price/Cash flow per share||12.78|
|Book value per share||41.62|
|Tangible book value per share||8.09|
Balance sheet in USD
|Total debt/total equity||1.11|
|Total debt/total capital||0.5267|
Growth rates in USD
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 26.58% and 13.06%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Biotechnology & Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, dividend per share growth is above the industry average relative to its peers, while earnings per share growth is in-line with the industry average.
|Div yield(5 year avg)||1.91%|
|Div growth rate (5 year)||48.17%|
|Payout ratio (TTM)||39.00%|
|EPS growth(5 years)||20.46|
|EPS (TTM) vs |
TTM 1 year ago